Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MDK | P21741 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.33 |
| ▸ | KLK7 | P49862 | 2/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18333352 | 0.91 | MDK (0.42) | LMNASMN1; SMN2MDK | |
| SCHEMBL16018267 | 0.90 | LMNA (0.32) | LMNASMN1; SMN2MDKGHSRLGALS8 | |
| SCHEMBL16018266 | 0.88 | LMNA (0.35) | LMNASMN1; SMN2MDKGHSRKLK7 | |
| SCHEMBL15369096 | 0.88 | LMNA (0.32) | LMNASMN1; SMN2 | |
| SCHEMBL16018194 | 0.88 | LMNA (0.32) | LMNASMN1; SMN2KLK7KLK5SELP | |
| SCHEMBL16018025 | 0.88 | GJB2 (0.38) | MDKSLC5A1SLC5A2 | |
| SCHEMBL16359395 | 0.86 | MDK (0.41) | LMNASMN1; SMN2MDK | |
| SCHEMBL15369054 | 0.85 | MDK (0.40) | LMNASMN1; SMN2MDK | |
| SCHEMBL12665274 | 0.84 | LMNA (0.37) | LMNASMN1; SMN2MDKGHSRLGALS8 | |
| SCHEMBL16018036 | 0.84 | MDK (0.34) | MDKSLC5A1SLC5A2MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345780-B2 | Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-05-24 | — | — | US | disclosed |
| US-20140256785-A1 | SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256785-A1 | SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, BST2, ANXA6 | LMNA 142/4885SMN1; SMN2 1354/4885MDK 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.